<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Immunology / Autoimmune diseases / Immunosuppressants / Monoclonal antibodies / RTT / Biotechnology / Infliximab / TNF inhibitor / Adalimumab / Arthritis
Date: 2015-06-19 09:18:02
Medicine
Clinical medicine
Immunology
Autoimmune diseases
Immunosuppressants
Monoclonal antibodies
RTT
Biotechnology
Infliximab
TNF inhibitor
Adalimumab
Arthritis

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 639,78 KB

Share Document on Facebook

Similar Documents

Large ElectronPositron Collider

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document